



For release: 2 October

genedrive plc ("genedrive" or the "Company")

genedrive to release Genedrive® Connect mobile app

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces phase 1 development of its Genedrive® connectivity solution, allowing for clinical data transmission from decentralised testing facilities. The new app is designed to enhance usability, but also provide functional surveillance-based data to further promote product adoption in the longer term.

Genedrive® Connect is an android-based mobile app, providing wireless data management to a single Genedrive® or a larger network installation. The phase 1 release of Genedrive® Connect allows Genedrive® users to manage patient demographics and user data, device and instrument data, and append this supplementary information to test results. The comprehensive data can then be transferred if needed to another local or distant location for rapid patient management or longer-term data storage.

Over the longer term, subsequent phases of Genedrive® Connect are planned to target collection of market surveillance capabilities for treatment facilities or funding agencies, to allow cost and performance analysis capabilities of their investments in Genedrive® technology.

David Budd, Chief Executive Officer of genedrive plc, said: “In discussions with our customers we identified that by developing a mobile app that allows added data management flexibility and results transmission, we could help improve the customer experience and help drive wider adoption. Genedrive® Connect offers immediate informatics benefits for Genedrive® users through the modern conveniences of app-based data management we all now take for granted. The ability to not just generate but transmit data for clinical action is an important component of our strategy to decentralise molecular diagnostics.”

Genedrive® Connect will be available to download via Google Play on either a dedicated smartphone or through an android BYOD (Bring Your Own Device) distribution model. The phase 1 release is targeted for selected distribution in Q1 2019 and general release in Q2 2019.

For more information on Genedrive® Connect and to see a video demonstration, please follow this link: <https://genedrive.com/genedrive-system/genedrive-connect.php>

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO

+44 (0)161 989 0245

Matthew Fowler: CFO

Peel Hunt LLP

James Steel

+44 (0)207 418 8900

Oliver Jackson

Stanford Capital

Patrick Claridge

+44 (0)203 815 8880

Consilium Strategic Communications

Chris Gardner

+44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com**Notes to Editors****About genedrive plc**

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India. Further details can be found at: www.genedriveplc.com and www.genedrive.com